Original price was: ₹1,150.00.₹989.00Current price is: ₹989.00.
GESTOSERV-300 SR
Salt Composition: Natural Micronised Progesterone 300 mg (Sustained Release, SR) (blister).
Brand: Leeford
10.0 tablet sr in 1 strip
Description
GESTOSERV-300 SR contains a high-dose, sustained-release bioidentical progesterone. It is prescribed for hormone replacement therapy, infertility, and menstrual-related disorders requiring prolonged progesterone support.
Uses
-
Support for luteal phase in infertility and IVF cycles
-
Maintenance of pregnancy (especially in high-risk cases)
-
Hormone replacement therapy (HRT) in postmenopausal women
-
Treatment of disorders like amenorrhea, abnormal uterine bleeding, or premenstrual syndrome.
Common Side Effects
-
Headache, dizziness, drowsiness, nausea, vomiting, bloating, abdominal cramps
-
Breast pain/tenderness, hair loss, acne, increased or irregular vaginal discharge, yeast infection
-
Mood changes (including depression), sleep disturbance, hot flashes, joint pain
-
Fluid retention/edema, weight gain, and possible constipation or diarrhea
-
Rare: visual changes, allergy, changes in menstrual bleeding pattern, skin rash, allergic reactions, and thromboembolic risks
Safety & Precautions
-
Avoid if history of breast/gynecologic cancer, unexplained vaginal bleeding, severe liver disease, or known allergy to progesterone.
-
May cause drowsiness or dizziness—avoid driving or machinery until response known.
-
Alcohol may enhance side effects; avoid concurrent use.
-
Monitor for mood changes, severe headaches, visual symptoms, or sudden swelling—report immediately
-
Drug interactions: Caution with anticonvulsants, antibiotics, antidepressants, and herbal supplements.
Ban Status in India
Natural micronised progesterone sustained release (300 mg) is not banned in India; it is widely prescribed and recognized for fertility, HRT, and menstrual disorders. Only use under medical supervision.
GESTOSERV-300 SR is a prescription, sustained-release progesterone tablet for female hormone support, safe for approved indications under healthcare guidance.






